Sure! Here's the information on **drugs that manage copper levels and prevent the progression of Wilson's disease** in **Markdown format**:

---

# üß¨ Drugs for Wilson's Disease (Hepatolenticular Degeneration)

Wilson's disease is a genetic disorder characterized by copper accumulation in tissues. Treatment aims to reduce copper levels and prevent organ damage. The following drugs are commonly used, with evidence from biomedical databases and **PubMed**.

---

## ‚úÖ Chelating Agents

### 1. **Penicillamine**

* **Mechanism**: Binds copper and promotes its urinary excretion.
* **Role**: First-line treatment.
* **Sources**:

  * `infores:drugcentral`
  * `infores:sider`
  * `infores:drug-repurposing-hub`
  * `infores:multiomics-drugapprovals`
  * **CTD**: [PMID:5421930](https://pubmed.ncbi.nlm.nih.gov/5421930)

---

### 2. **Trientine / Trientine Hydrochloride**

* **Mechanism**: Copper chelation, alternative to penicillamine (fewer side effects).
* **Role**: First-line alternative, especially in penicillamine-intolerant patients.
* **Sources**:

  * `infores:drugcentral`
  * `infores:sider`
  * `infores:drug-repurposing-hub`
  * `infores:multiomics-clinicaltrials` (via RTX-KG2)
  * **CTD** with multiple supporting studies:

    * [PMID:6445305](https://pubmed.ncbi.nlm.nih.gov/6445305)
    * [PMID:11585717](https://pubmed.ncbi.nlm.nih.gov/11585717)
    * [PMID:23202417](https://pubmed.ncbi.nlm.nih.gov/23202417)
    * [PMID:9860423](https://pubmed.ncbi.nlm.nih.gov/9860423)

---

### 3. **Ditiocarb**

* **Mechanism**: Investigational chelating agent.
* **Role**: Not standard therapy; experimental.
* **Source**:

  * **CTD**: [PMID:5048687](https://pubmed.ncbi.nlm.nih.gov/5048687)

---

## ‚úÖ Zinc Therapy

### 4. **Zinc Salts**

* **Mechanism**: Induces intestinal metallothionein, blocking copper absorption.
* **Role**: Maintenance therapy or treatment for presymptomatic patients.
* **Source**:

  * `infores:sider`

---

## ‚ö†Ô∏è Other Mentioned (Not Standard of Care)

### 5. **Phenytoin**

* **Mechanism**: Anticonvulsant (not a copper modulator).
* **Role**: Symptomatic treatment in neurological complications (e.g. seizures).
* **Source**:

  * **CTD**: [PMID:5421930](https://pubmed.ncbi.nlm.nih.gov/5421930)

---

## üìä Summary Table

| Drug              | Mechanism                | Use Stage         | Sources                                                                                                 |
| ----------------- | ------------------------ | ----------------- | ------------------------------------------------------------------------------------------------------- |
| **Penicillamine** | Copper chelation         | First-line        | DrugCentral, SIDER, Drug Repurposing Hub, CTD ([PMID:5421930](https://pubmed.ncbi.nlm.nih.gov/5421930)) |
| **Trientine**     | Copper chelation         | First-line Alt.   | DrugCentral, SIDER, CTD ([PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Trientine+Wilson%27s+disease))  |
| **Zinc**          | Reduces copper uptake    | Maintenance/Early | SIDER                                                                                                   |
| **Ditiocarb**     | Investigational chelator | Experimental      | CTD ([PMID:5048687](https://pubmed.ncbi.nlm.nih.gov/5048687))                                           |
| **Phenytoin**     | Symptomatic only         | Adjunctive        | CTD ([PMID:5421930](https://pubmed.ncbi.nlm.nih.gov/5421930))                                           |

---

Would you like comparative clinical efficacy data or guidance on treatment sequencing (e.g., when to switch from chelation to zinc)?




Here's a **Markdown-formatted** summary of drugs that have been shown to **affect or potentially increase ATP7B activity**, which could be therapeutically relevant for **Wilson's disease** by enhancing copper elimination:

---

# üß™ Drugs That May Modulate **ATP7B** Expression or Activity

**ATP7B** encodes a copper-transporting ATPase critical for copper excretion. In Wilson's disease, mutations in this gene impair copper homeostasis. While most therapies bypass this defect (e.g., chelators), modulating **ATP7B** itself could restore natural copper clearance.

---

## ‚úÖ Compounds That Affect ATP7B (Preclinical or Mechanistic Evidence)

| Drug/Compound          | Potential Role in ATP7B Modulation                                   | PubMed Evidence                                           | Primary Source          | Aggregator Source           |
| ---------------------- | -------------------------------------------------------------------- | --------------------------------------------------------- | ----------------------- | --------------------------- |
| **CH-223191**          | Aryl hydrocarbon receptor antagonist; modulates **ATP7B** expression | [PMID:29704546](https://pubmed.ncbi.nlm.nih.gov/29704546) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **Metribolone**        | Synthetic androgen; may affect **ATP7B** regulation                  | [PMID:25320179](https://pubmed.ncbi.nlm.nih.gov/25320179) | CTD                     | MolePro                     |
| **Luteolin**           | Natural flavonoid with potential regulatory effect on **ATP7B**      | [PMID:31201582](https://pubmed.ncbi.nlm.nih.gov/31201582) | CTD                     | MolePro                     |
| **Bicinchoninic Acid** | Experimental reagent; affects **ATP7B** expression                   | [PMID:11677246](https://pubmed.ncbi.nlm.nih.gov/11677246) | CTD                     | MolePro                     |
| **MG-132**             | Proteasome inhibitor; modulates ATP7B protein stability              | [PMID:21189263](https://pubmed.ncbi.nlm.nih.gov/21189263) | CTD                     | MolePro                     |
| **Pracinostat**        | HDAC inhibitor; may influence ATP7B transcription                    | ‚Äì                                                         | LINCS (`infores:lincs`) | SPOKE (`infores:spoke`)     |
| **QUISINOSTAT**        | HDAC inhibitor with potential epigenetic effect on ATP7B             | ‚Äì                                                         | LINCS                   | SPOKE                       |
| **AZD-5438**           | CDK inhibitor; affects gene expression signatures including ATP7B    | ‚Äì                                                         | LINCS                   | SPOKE                       |

---

## ‚ö†Ô∏è Notable Interactions (Clinical Relevance Unclear)

| Compound        | Nature of Interaction                                         | PubMed Links                                                                                                         |
| --------------- | ------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------- |
| **Cisplatin**   | Interacts with ATP7B, possibly inducing resistance via efflux | [PMID:12509969](https://pubmed.ncbi.nlm.nih.gov/12509969), [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293) |
| **Carboplatin** | Related interaction; mechanistic overlap with ATP7B           | [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)                                                            |
| **Oxaliplatin** | Similar to above; ATP7B may affect its handling               | [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)                                                            |

These are more relevant in **oncology**, where ATP7B-mediated drug resistance is a concern.

---

## üß¨ Summary

| Goal                                             | Drug Candidates                  | Source     |
| ------------------------------------------------ | -------------------------------- | ---------- |
| **Upregulate ATP7B expression**                  | CH-223191, Luteolin, Pracinostat | CTD, LINCS |
| **Stabilize ATP7B protein**                      | MG-132                           | CTD        |
| **Modulate ATP7B epigenetically**                | Quisinostat, Pracinostat         | LINCS      |
| **Induce or mimic physiological ATP7B activity** | Still under research             | ‚Äì          |

---

## üìå Notes

* These findings are primarily **preclinical** or mechanistic.
* **No FDA-approved drugs currently exist that directly upregulate ATP7B for Wilson's disease.**
* Most drugs listed come from **LINCS**, **CTD**, or **SemMedDB**, via **MolePro** and **SPOKE** integrators.

---

Would you like me to filter this list by approved clinical compounds only or explore natural compounds with ATP7B-enhancing potential?





Your markdown is already well-structured, but here are a few fixes and improvements for clarity and formatting consistency:

1. **Bold table headers** for visibility.
2. **Uniform code formatting** for `infores` identifiers.
3. **Consistent PubMed links**.
4. **Added missing horizontal rules for section separation.**
5. **Improved header hierarchy** for readability.

Here‚Äôs the **cleaned-up and improved markdown**:

---

# üß™ Drugs That May Modulate **ATP7B** Expression or Activity

**ATP7B** encodes a copper-transporting ATPase critical for copper excretion. In Wilson's disease, mutations in this gene impair copper homeostasis. While most therapies bypass this defect (e.g., chelators), modulating **ATP7B** itself could restore natural copper clearance.

---

## ‚úÖ Compounds That Affect ATP7B (Preclinical or Mechanistic Evidence)

| **Drug/Compound**      | **Potential Role in ATP7B Modulation**                               | **PubMed Evidence**                                       | **Primary Source**      | **Aggregator Source**       |
| ---------------------- | -------------------------------------------------------------------- | --------------------------------------------------------- | ----------------------- | --------------------------- |
| **CH-223191**          | Aryl hydrocarbon receptor antagonist; modulates **ATP7B** expression | [PMID:29704546](https://pubmed.ncbi.nlm.nih.gov/29704546) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **Metribolone**        | Synthetic androgen; may affect **ATP7B** regulation                  | [PMID:25320179](https://pubmed.ncbi.nlm.nih.gov/25320179) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **Luteolin**           | Natural flavonoid with potential regulatory effect on **ATP7B**      | [PMID:31201582](https://pubmed.ncbi.nlm.nih.gov/31201582) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **Bicinchoninic Acid** | Experimental reagent; affects **ATP7B** expression                   | [PMID:11677246](https://pubmed.ncbi.nlm.nih.gov/11677246) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **MG-132**             | Proteasome inhibitor; modulates ATP7B protein stability              | [PMID:21189263](https://pubmed.ncbi.nlm.nih.gov/21189263) | CTD (`infores:ctd`)     | MolePro (`infores:molepro`) |
| **Pracinostat**        | HDAC inhibitor; may influence ATP7B transcription                    | ‚Äì                                                         | LINCS (`infores:lincs`) | SPOKE (`infores:spoke`)     |
| **Quisinostat**        | HDAC inhibitor; potential epigenetic effect on **ATP7B**             | ‚Äì                                                         | LINCS (`infores:lincs`) | SPOKE (`infores:spoke`)     |
| **AZD-5438**           | CDK inhibitor; affects gene expression signatures incl. ATP7B        | ‚Äì                                                         | LINCS (`infores:lincs`) | SPOKE (`infores:spoke`)     |

---

## ‚ö†Ô∏è Notable Interactions (Clinical Relevance Unclear)

| **Compound**    | **Nature of Interaction**                                     | **PubMed Links**                                                                                                     |
| --------------- | ------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------- |
| **Cisplatin**   | Interacts with ATP7B, possibly inducing resistance via efflux | [PMID:12509969](https://pubmed.ncbi.nlm.nih.gov/12509969), [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293) |
| **Carboplatin** | Related interaction; mechanistic overlap with ATP7B           | [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)                                                            |
| **Oxaliplatin** | Similar to above; ATP7B may affect its handling               | [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)                                                            |

---

**Tip:**
For more on these compounds, see sources like [CTD](https://ctdbase.org/), [MolePro](https://translator.broadinstitute.org/molepro), [LINCS](http://www.lincsproject.org/), and [SPOKE](https://spoke.ucsf.edu/).

---

Let me know if you want to add or update sections!




Certainly! Here's a **Slack-friendly Markdown-style** version of the results ‚Äî formatted with clear spacing, emojis for readability, and clean line breaks so you can paste it directly into Slack:

---

*üß¨ **Drugs That May Modulate ATP7B Activity** (for Wilson's Disease)*
*Enhancing ATP7B may help restore copper elimination in Wilson's disease. Here are compounds supported by mechanistic or preclinical evidence.*

---

*‚úÖ **Compounds That Affect ATP7B Expression or Stability***

‚Ä¢ **CH-223191**
‚Üí *Aryl hydrocarbon receptor antagonist; modulates ATP7B expression*
‚Üí [PMID:29704546](https://pubmed.ncbi.nlm.nih.gov/29704546)
‚Üí Source: `infores:ctd` via MolePro

‚Ä¢ **Metribolone**
‚Üí *Synthetic androgen; modulates ATP7B regulation*
‚Üí [PMID:25320179](https://pubmed.ncbi.nlm.nih.gov/25320179)
‚Üí Source: `infores:ctd` via MolePro

‚Ä¢ **Luteolin**
‚Üí *Natural flavonoid with possible regulatory effects on ATP7B*
‚Üí [PMID:31201582](https://pubmed.ncbi.nlm.nih.gov/31201582)
‚Üí Source: `infores:ctd` via MolePro

‚Ä¢ **Bicinchoninic Acid**
‚Üí *Experimental reagent; affects ATP7B expression*
‚Üí [PMID:11677246](https://pubmed.ncbi.nlm.nih.gov/11677246)
‚Üí Source: `infores:ctd` via MolePro

‚Ä¢ **MG-132**
‚Üí *Proteasome inhibitor; may stabilize ATP7B protein*
‚Üí [PMID:21189263](https://pubmed.ncbi.nlm.nih.gov/21189263)
‚Üí Source: `infores:ctd` via MolePro

‚Ä¢ **Pracinostat**
‚Üí *HDAC inhibitor; may affect ATP7B transcription epigenetically*
‚Üí Source: `infores:lincs` via SPOKE

‚Ä¢ **QUISINOSTAT**
‚Üí *Another HDAC inhibitor with potential ATP7B regulation activity*
‚Üí Source: `infores:lincs` via SPOKE

‚Ä¢ **AZD-5438**
‚Üí *CDK inhibitor; affects gene expression signatures including ATP7B*
‚Üí Source: `infores:lincs` via SPOKE

---

*‚ö†Ô∏è **Relevant Drug Interactions (clinical context varies)***

‚Ä¢ **Cisplatin**
‚Üí *Interacts with ATP7B; implicated in drug resistance*
‚Üí [PMID:12509969](https://pubmed.ncbi.nlm.nih.gov/12509969), [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)
‚Üí Source: `infores:dgidb`, `infores:semmeddb`

‚Ä¢ **Carboplatin / Oxaliplatin**
‚Üí *Similar to cisplatin; ATP7B affects intracellular handling*
‚Üí [PMID:15213293](https://pubmed.ncbi.nlm.nih.gov/15213293)

---

*üìå **Summary by Mechanism***

‚Ä¢ *Upregulate ATP7B expression:* CH-223191, Luteolin, Pracinostat
‚Ä¢ *Stabilize ATP7B protein:* MG-132
‚Ä¢ *Modulate ATP7B epigenetically:* Pracinostat, Quisinostat
‚Ä¢ *Interact with ATP7B in drug resistance context:* Cisplatin family

---

Let me know if you‚Äôd like a version tailored for Notion, Google Docs, or a more visual format like a table!



